• 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Expert opinion on biological therapy >Nimotuzumab for pediatric diffuse intrinsic pontine gliomas.
【24h】

Nimotuzumab for pediatric diffuse intrinsic pontine gliomas.

机译：尼妥珠单抗用于小儿弥漫性桥脑神经胶质瘤。

获取原文
获取原文并翻译 | 示例
       
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

INTRODUCTION: Diffuse intrinsic pontine gliomas (DIPG) have a poor prognosis: the median survival rate is less than one year. Radiotherapy is the only effective treatment affording an overall survival of 6 - 9 months. So far, no improvement has been achieved with the addition of single/poly-chemotherapy regimens. An urgent need is to advance in this field, from both the biological and the clinical points of view. AREAS COVERED: Among the few studies providing biological information on DIPG, Gilbertson's group demonstrated a significant increase in EGFR expression. The activity of nimotuzumab, a humanized anti-EGFR monoclonal antibody, was therefore studied within a Phase II trial in 47 relapsing pediatric patients with DIPG and high-grade gliomas, showing an interesting, persistent response, especially in the first group treated. A multicenter exploratory study combining nimotuzumab and radiotherapy showed disease control and an overall patient survival similar to previous experiences along with an improvement in the quality of patient survival and no severe side effects. EXPERT OPINION: We recommend considering this combination in the armamentarium against DIPG. It might be improved by adding other target drugs/low-toxicity chemotherapy regimens with a synergistic effect with the anti-EGFR component.
机译：简介：弥漫性桥脑神经胶质瘤（DIPG）预后较差：中位生存期不到一年。放射疗法是唯一可以提供6-9个月总生存期的有效治疗方法。到目前为止，单药/多药化疗方案没有取得任何改善。从生物学和临床的观点来看，迫切需要在该领域中发展。覆盖的区域：在提供DIPG生物学信息的少数研究中，Gilbertson的研究小组证明了EGFR表达的显着增加。因此，在一项II期临床试验中，对47位患有DIPG和高级别神经胶质瘤的复发性儿科患者进行了II期临床试验，研究了人源化抗EGFR单克隆抗体nimotuzumab的活性，显示出有趣的持续应答，尤其是在治疗的第一组中。一项将尼莫妥珠单抗和放疗相结合的多中心探索性研究显示，疾病控制和患者总体生存与以前的经历相似，患者生存质量得到改善，并且没有严重的副作用。专家意见：我们建议在针对DIPG的军械库中考虑这种组合。通过添加与抗EGFR成分具有协同作用的其他靶标药物/低毒性化疗方案，可能会改善这种情况。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号